Liraglutide for weight management: a critical review of the evidence

Cited by papers we hold 8

• Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent · 2023
  No notice
• Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials · 2023
  No notice
• Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes · 2022
  No notice
• Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity · 2022
  No notice
• Fecal Microbiota Transplantation as New Therapeutic Avenue for Human Diseases · 2022
  No notice
• Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice · 2022
  No notice
• Impact of Fecal Microbiota Transplantation on Obesity and Metabolic Syndrome—A Systematic Review · 2019
  No notice
• The Discovery and Development of Liraglutide and Semaglutide · 2019
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.